Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial

Author(s): Riecke, Armin; Robrecht, Sandra; Yosifov, Deyan Y.; Schneider, Christof; Giza, Adam; Müller, Lothar; Vehling-Kaiser, Ursula; Eckart, Michael; Freier, Werner; Schöttker, Björn; Gaska, Tobias; Reiser, Marcel; Fink, Anna-Maria; Fischer, Kirsten; Eichhorst, Barbara; Hallek, Michael; Langerbeins, Petra; Stilgenbauer, Stephan; Tausch, Eugen;
Source: Blood (2026) 148 (9): 1108–1114.
Original Article
Professional photo of Maem Hussein, MD

Dr. Maen Hussein's Thoughts

Patients with high-risk asymptomatic early-stage CLL (del(17p) or mutated TP53) do not derive an EFS benefit from early ibrutinib treatment. Watch-and-wait remains standard for early-stage CLL regardless of genetic subgroup; genetic test findings must not prompt early treatment

ABSTRACT

Watch-and-wait is standard of care in asymptomatic early-stage chronic lymphocytic leukemia (CLL). The CLL12 trial investigated ibrutinib vs placebo for patients with early-stage CLL with intermediate to very high risk of progression, improving event-free survival (EFS) but not overall survival (OS). Building on these findings, our analysis examined whether a benefit could be identified within distinct genetic subgroups. After a median follow-up of 69.3 months, there were 166 EFS and 32 OS events in 515 trial patients. In the placebo arm, del(17p), del(11q), +12, unmutated immunoglobulin heavy variable chain (U-IGHV), and mutations in NOTCH1, ATM, NRAS/KRAS/BRAF, and NFKBIE correlated with shorter EFS. With ibrutinib, only del(17p) and TP53 and NFKBIE mutations significantly compromised EFS. Ibrutinib offered substantial EFS benefit in subgroups with U-IGHV, del(11q), +12, NOTCH1, ATM, and NFKBIE mutations. No EFS improvement was seen for patients with asymptomatic early-stage CLL with del(17p) or TP53 mutations. Ibrutinib provided no OS benefits in any genetic subgroup. Multivariable analysis revealed ibrutinib treatment as independent favorable factor for EFS, whereas U-IGHV, del(17p), POT1, RAS/RAF, and NFKBIE mutations were adverse prognostic factors. Results confirm watch-and-wait as standard of care for patients with early-stage CLL, especially in high-risk CLL characterized by del(17p) and/or mutated TP53. This trial was registered at the European Union Drug Regulating Authorities Clinical Trials Database (2013-003211-22).

Author Affiliations

11Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany2German Military Hospital Ulm, Federal Armed Forces, Ulm, Germany; 21Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany; 32German Military Hospital Ulm, Federal Armed Forces, Ulm, Germany; 43Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; 51Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany4German Cancer Research Center, Heidelberg, Germany; 64German Cancer Research Center, Heidelberg, Germany; 75Study Centrum Unter Ems, Practice for Oncology and Hematology, Leer, Germany; 86Outpatient Clinic, Landshut, Germany; 97Practice for Oncology and Hematology, Erlangen, Germany; 108Medicinum, Hildesheim, Germany; 119Practice for Hematology and Oncology, Würzburg, Germany; 1210Department of Hematology and Oncology, Brüderkrankenhaus, Paderborn, Germany; 1311Practice for Oncology and Hematology, Cologne, Germany; 14Please enter your affiliations

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

CLL17 shows that fixed‑duration venetoclax–obinutuzumab or venetoclax–ibrutinib is noninferior to continuous ibrutinib upfront, with 3‑year PFS ≈80% across all arms. The big difference is depth of response, undetectable MRD was 73% with venetoclax–obinutuzumab, 47% with venetoclax–ibrutinib, and 0% with ibrutinib. Toxicities tracked with mechanism (more cytopenias/infusion reactions with ven‑obinutuzumab, more cardiac events with ibrutinib). Overall, this strongly supports time‑limited therapy as a frontline standard for many chronic lymphocytic leukemia (CLL) patients.

Read More »

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????

Read More »

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial Open Access

Acalabrutinib in patients aged ≥80 years demonstrated 12-month progression-free (PFS) and overall survival (OS) rates of 93.3% and 95.7%, respectively, after a median follow-up of 19 months. Adverse events were severe but rarely included major bleeding or atrial fibrillation. Patient-reported quality of life improved, including amerlioration of frailty.

Read More »